- Symbol
- CUE
- Segment MIC
- XNCM
- ISIN
- US22978P2056
- Trading currency
- USD
XNCM:CUE — listed on NASDAQ CAPITAL MARKET
Cue Biopharma, Inc. is a biotechnology company focused on developing precision immuno-engineered therapies for allergic and autoimmune diseases. Its lead product, CUE-221, is an anti-IgE antibody in Phase 2 development aimed at treating IgE-mediated allergic diseases. The company also utilizes its Immuno-STAT® platform to create therapies that selectively target disease-specific T cells for autoimmune conditions, with CUE-401, a bifunctional IL-2 and TGF-β program, advancing toward Phase 1 development. Cue Biopharma operates primarily in the United States.